Detection of Occult Tumour Cells in Bone Marrow and Blood in Breast Cancer Patients

References

• Henderson I. C., Canellos G. P. Cancer of the breast. N Engl J Med 1980; 302: 17–30
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. Lancet 1992; 339: 1–15
   PubMed Web of Science ®Google Scholar
• McGuire W., Abeloff M. D., Fisher B., Glick J. H., Henderson IC, Osborne C. K. Adjuvant therapy in node-negative breast cancer. Breast Cancer Res Treat 1989; 13: 97–115
   PubMedGoogle Scholar
• Fisher B., Dignam J., Mamounas E. P. Sequential methotrexate and fluorouracil for the treatment of node-negative cancer patients with estrogen receptor-negative tumors: Eight-years' results from national surgery adjuvant breast and bowel project (NSABP) B-13 and first report of findings from NSABP-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil. J Clin Oncol 1996; 14: 1982–92
   PubMed Web of Science ®Google Scholar
• McGuire W. L., Tandon A. K., Allred D. C., Chamness G. C., Clark G. M. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 1006–15
   PubMed Web of Science ®Google Scholar
• Gundersen S., Bøhler P., Hannisdal E., Høst H. Tumour size and histologic grading in node-negative breast cancer. Prognostic and therapeutic implications. Tidsskr Nor Laegeforen 1996; 116: 222–5
   PubMedGoogle Scholar
• Mansi J. L., Easton D., Berger U. Bone marrow micrometastases in primary breast cancer: Prognostic significance after 6 years follow-up. Eur J Cancer 1991; 27: 1552–5
   PubMed Web of Science ®Google Scholar
• Diel I. J., Kaufmann M., Costa S. D., Bastert G. Monoclonal antibodies to detect breast cancer cells in bone marrow. Important advances in oncology, V. T. DeVita, S. Hellman, J. B. Rosenberg. Lippincott Company, Philadelphia 1994; 64–143
   Google Scholar
• Schlimok G., Funke I., Holzmann B. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cy-tokeratin and in vivo labeling with anti-17-lA monoclonal antibodies. Proc Natl Acad Sci USA 1987; 84: 8672–6
   PubMed Web of Science ®Google Scholar
• Cote R. J., Rosen P. P., Lesser M. L., Old L. J., Osborne M. P. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749–56
   PubMed Web of Science ®Google Scholar
• Harbeck N., Untech M., Pache L., Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 1994; 69: 566–71
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Rill D. R., Moen R. C. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85–6
   PubMed Web of Science ®Google Scholar
• Moss T. J., Ross A. A. The risk of tumor cell contamination in peripheral blood stem cell collections. J Hematotherapy 1992; 1: 225–32
   PubMedGoogle Scholar
• Shpall E. J., Jones R. B. Release of tumor cells from bone marrow. Blood 1994; 83: 623–5
   PubMed Web of Science ®Google Scholar
• Pantel K., Schlimok G., Angstwurm M. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow. J Hematother 1994; 3: 165–73
   PubMedGoogle Scholar
• Naume B., Borgen E., Beiske K. Detection of isolated breast cancer cells in peripheral blood or bone marrow by immunomagnetic techniques. J Hematother 1996, in press.
   Google Scholar
• Gribben J. G., Neuberg D., Freedman A. S. Detection by polymerase chain reaction of residual cells with bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–57
   PubMed Web of Science ®Google Scholar
• Datta Y. H., Adams P. T., Drobyski W. R., Ethier S. P., Terry V. H., Roth M. S. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475–82
   PubMed Web of Science ®Google Scholar
• Fields K. K., Elfenbein G. J., Trudeau W. L., Perkins J. B., Janssen W. E., Moscinski L. C. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1868–76
   PubMed Web of Science ®Google Scholar
• Krismann M., Todt B., Schröder J. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination. J Clin Oncol 1995; 13: 2769–75
   PubMedGoogle Scholar
• Neumaier M., Gerhard M., Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene 1995; 159: 43–7
   PubMed Web of Science ®Google Scholar
• Gerhard M., Juhl H., Kalthoff H., Schreiber H. W., Wagener C., Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994; 12: 725–9
   PubMed Web of Science ®Google Scholar
• Ross A. A., Cooper B. W., Lazarus H. M. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–10
   PubMed Web of Science ®Google Scholar
• Sharp J. G., Mann S. L., Murphy B., Weekes C. Culture methods for the detection of minimal tumor contamination of hematopoietic harvests: A review. J Hematother 1995; 4: 141–8
   PubMedGoogle Scholar
• Kvalheim G., Ugland K., Erikstein B. Detection of micrometastasis in bone marrow and blood in high-risk stage II breast cancer patients (abstract). First International Symposium on Minimal Residual Cancer 1996; 3: 21
   Google Scholar
• Kvalheim G., Wang M. Y., Pharo A. Purging of tumor cells from leukapheresis products: Experimental and clinical aspects. J Hematother 1996; 5: 427–36
   PubMedGoogle Scholar
• Schlimok K., Pantel K., Loibner H., Fackler-Schwalbe I., Rieth-Muller G. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours. Eur J Cancer 1995; 11: 1799–803
   Google Scholar
• Pantel K., Felber E., Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994; 3: 315–22
   PubMedGoogle Scholar
• Pantel K., Schlimok G., Braun S. Differential expression of proliferation-associated molecules in individual micro-metastatic carcinoma cells. JNCI 1993; 17: 1419–23
   Google Scholar
• Smeland E. B., Funderud S., Kvalheim G. Isolation and characterization of human hematopoietic progenitor cells; An efficient method for positive selection of CD34+cells. Leukemia 1992; 6: 845–52
   PubMedGoogle Scholar
• Fodstad Ø, Høifødt H., Rye P. D., Trones G. E., Beiske K. New immunobead techniques for sensitive detection of malignant cells in blood and bone marrow. Proceedings of the American Association for Cancer Research (abstract) 1996; 37: 217
   Google Scholar